These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30128069)

  • 1. Investigating the Behavior of Published PAINS Alerts Using a Pharmaceutical Company Data Set.
    Vidler LR; Watson IA; Margolis BJ; Cummins DJ; Brunavs M
    ACS Med Chem Lett; 2018 Aug; 9(8):792-796. PubMed ID: 30128069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS.
    Capuzzi SJ; Muratov EN; Tropsha A
    J Chem Inf Model; 2017 Mar; 57(3):417-427. PubMed ID: 28165734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring Activity Profiles of PAINS and Their Structural Context in Target-Ligand Complexes.
    Siramshetty VB; Preissner R; Gohlke BO
    J Chem Inf Model; 2018 Sep; 58(9):1847-1857. PubMed ID: 30105913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward an Understanding of Pan-Assay Interference Compounds and Promiscuity: A Structural Perspective on Binding Modes.
    Bolz SN; Adasme MF; Schroeder M
    J Chem Inf Model; 2021 May; 61(5):2248-2262. PubMed ID: 33899463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to Triage PAINS-Full Research.
    Dahlin JL; Walters MA
    Assay Drug Dev Technol; 2016 Apr; 14(3):168-74. PubMed ID: 26496388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on The Ecstasy and Agony of Assay Interference Compounds.
    Kenny PW
    J Chem Inf Model; 2017 Nov; 57(11):2640-2645. PubMed ID: 29048168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity artifacts in drug discovery and different facets of compound promiscuity.
    Bajorath J
    F1000Res; 2014; 3():233. PubMed ID: 25339989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoting GAINs (Give Attention to Limitations in Assays) over PAINs Alerts: no PAINS, more GAINs.
    Choo MZY; Chai CLL
    ChemMedChem; 2022 Apr; 17(7):e202100710. PubMed ID: 35146933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filtering promiscuous compounds in early drug discovery: is it a good idea?
    Senger MR; Fraga CA; Dantas RF; Silva FP
    Drug Discov Today; 2016 Jun; 21(6):868-72. PubMed ID: 26880580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Pan-Assay INterference compoundS (PAINS) Using an MD-Based Protocol.
    Magalhães PR; Reis PBPS; Vila-Viçosa D; Machuqueiro M; Victor BL
    Methods Mol Biol; 2021; 2315():263-271. PubMed ID: 34302681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts.
    Yang ZY; Yang ZJ; He JH; Lu AP; Liu S; Hou TJ; Cao DS
    Drug Discov Today; 2021 Jun; 26(6):1353-1358. PubMed ID: 33581116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Nuisance Substructures and Aggregators in a Comprehensive Database of Food Chemical Compounds.
    Kaya I; Colmenarejo G
    J Agric Food Chem; 2020 Aug; 68(33):8812-8824. PubMed ID: 32687707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds.
    Jasial S; Hu Y; Bajorath J
    J Med Chem; 2017 May; 60(9):3879-3886. PubMed ID: 28421750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
    Baell JB; Holloway GA
    J Med Chem; 2010 Apr; 53(7):2719-40. PubMed ID: 20131845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical Matter.
    Jasial S; Gilberg E; Blaschke T; Bajorath J
    J Med Chem; 2018 Nov; 61(22):10255-10264. PubMed ID: 30422657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.
    Gilberg E; Gütschow M; Bajorath J
    J Med Chem; 2018 Feb; 61(3):1276-1284. PubMed ID: 29328660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology.
    Gilberg E; Jasial S; Stumpfe D; Dimova D; Bajorath J
    J Med Chem; 2016 Nov; 59(22):10285-10290. PubMed ID: 27809519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research.
    Pouliot M; Jeanmart S
    J Med Chem; 2016 Jan; 59(2):497-503. PubMed ID: 26313340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries.
    Liu R; Yu X; Wallqvist A
    J Cheminform; 2015; 7():4. PubMed ID: 25717346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.